CAMPATH-1H [alemtuzumab] compassionate treatment in patients with prolymphocytic leukemia (PLL) who have failed at least one prior regimen and chronic lymphocytic leukemia (CLL) patients who have failed fludarabine therapy.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2015
At a glance
- Drugs Alemtuzumab (Primary)
- Indications B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 27 Nov 2006 New trial record.